丙卡特罗联合孟鲁斯特治疗儿童中度持续性支气管哮喘疗效观察

Efficacy of procaterol and montelukast on children with moderate persistent asthma

目的：探讨丙卡特罗联合孟鲁斯特对中度持续性支气管哮喘患儿的疗效及其对肺功能的改善作用。方法选择2014年1月至2014年12月嵊州市妇幼保健院接诊的86例中度持续性支气管哮喘患儿进行研究，按入院时间先后分为对照组和观察组，每组各43例。观察组采用丙卡特罗联合孟鲁斯特治疗，对照组采用单纯的丙卡特罗进行治疗。比较两组患儿的咳嗽缓解时间以及消失时间、治疗后肺功能改善情况、临床疗效、治疗一个月后哮喘控制情况。结果治疗后，观察组咳嗽缓解时间以及消失时间短于对照组，两组比较差异有统计学意义（t ＝4．4185、3．7844，P ＝0．0000、0．0003）。观察组用力呼吸最大流速（PEF）、用力肺活量（FVC）、第一秒用力呼吸容积（FEV1）、用力呼吸一秒率（FEV1／FVC）的占预计值均较对照组高，两组差异均有统计学意义（均 P ＜0．05）。观察组总有效率（93．00％）较对照组的总有效率（74．40％）高，两组比较差异有统计学意义（u ＝2．2232，P ＝0．0262）。治疗一个月后，观察组患儿的基本控制率（88．37％）比对照组（67．40％）高。两组差异有统计学意义（u ＝2．3866，P ＝0.0170）；观察组不良反应率（6．98％）明显低于对照组（51．16％），两组差异有统计学意义（P ＜0.005）。结论丙卡特罗联合孟鲁斯特治疗中度持续性支气管哮喘，能提高临床疗效，安全性好，不良反应情况较少，值得临床推广。

Objective To investigate the efficacy of procaterol and montelukast on lung function in children with moderate persistent asthma.Methods 86 children with moderate persistent asthma from January 2014 to December 2014 in our hospital were studied,and according to the random number table method,they were divided into the control group and the observation group,43 cases in each group.The observation group was treated with procaterol combined with montelukast,the control group was treated with procaterol.The cough relief and disappearance time,the improvement of pulmonary function after treatment,the clinical effect and the control of asthma after one month of the two groups were compared.Results After treatment,children cough relief and disappeared time of the observation group was significantly shorter than the control group （t =4.418 5,3.784 4,P =0.000 0,0.000 3）.After treatment, the pulmonary function was found to improve the situation of the observation group being good than the control group, PEF,FVC,FEV1 ,FEV1 /FVC predicted values were significantly higher than the control group （all P 〈0.05）.The total effective rate of the observation group （93.00%）was significantly higher than 74.40% of the control group （u =2.223 2,P =0.026 2）.After one month of treatment,the basic control rate of the observation group（88.37%） was significantly higher than 67.40% of the control group（u =2.386 6,P =0.017 0）.The incidence rate of adverse reactions of the observation group （6.98%）was significantly lower than 51.16% of the control group（P 〈0.05）. Conclusion Procaterol combined with montelukast in the treatment of children with moderate persistent bronchial asthma can improve clinical efficacy,safety,and improve symptom control rate,it is worthy of promotion.